BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37388798)

  • 21. Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement.
    Takahashi M; Sumitani R; Hori T; Murai J; Kawata S; Oura M; Sogabe K; Harada T; Fujii S; Miki H; Kagawa K; Abe M; Nakamura S
    J Med Invest; 2021; 68(1.2):196-201. PubMed ID: 33994471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis.
    Meeuwes FO; Brink M; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer L; Woei-A-Jin S; Visser O; Oostvogels R; Jansen PM; Diepstra A; Snijders TJF; Plattel WJ; Huls GA; Vermaat JSP; Nijland M
    Eur J Cancer; 2022 Nov; 176():100-109. PubMed ID: 36208568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
    Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
    Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
    d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
    J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
    Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
    Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL).
    Kim KH; Lee JH; Lee M; Kim HG; Do YR; Park Y; Oh SY; Shin HJ; Kim WS; Park SK; Kong JH; Park MR; Yang DH; Kwak JY; Kang HJ; Mun YC; Won JH
    Cancer Res Treat; 2023 Jan; 55(1):304-313. PubMed ID: 35381164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
    Cairoli R; Grillo G; Tedeschi A; Gargantini L; Marenco P; Tresoldi E; Barbarano L; Nosari AM; Morra E
    Bone Marrow Transplant; 2002 Mar; 29(6):473-7. PubMed ID: 11960265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index.
    Bertz H; Zeiser R; Lange W; Fetscher S; Waller CF; Finke J
    Ann Oncol; 2004 Sep; 15(9):1419-24. PubMed ID: 15319249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged resolution of hemophagocytic lymphohistiocytosis following myeloablative chemotherapy and subsequent autologous peripheral blood stem cell transplantation.
    Ohga S; Nomura A; Kai T; Matsuzaki A; Inaba S; Suda M; Ueda K
    Bone Marrow Transplant; 1997 Mar; 19(6):633-5. PubMed ID: 9085745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
    Mercadal S; Briones J; Xicoy B; Pedro C; Escoda L; Estany C; Camós M; Colomo L; Espinosa I; Martínez S; Ribera JM; Martino R; Gutiérrez-García G; Montserrat E; López-Guillermo A;
    Ann Oncol; 2008 May; 19(5):958-63. PubMed ID: 18303032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemophagocytic lymphohistiocytosis: a rare complication of autologous stem cell transplantation.
    ColiŢă A; ColiŢă A; Dobrea CM; Tănase AD; Şaguna C; Ghimici CG; Manolache RM; Angelescu S; Barbu D; Grădinaru F; Lupu AR
    Rom J Morphol Embryol; 2016; 57(2):551-7. PubMed ID: 27516033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
    Ahn JS; Yang DH; Jung SH; Chae YS; Sohn SK; Yhim HY; Kwak JY; Lee SR; Kim YK; Kim HJ; Lee JJ
    Ann Hematol; 2013 Jun; 92(6):789-97. PubMed ID: 23358616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up.
    Zhu F; Li Q; Pan H; Xiao Y; Liu T; Liu X; Li J; Wu G; Zhang L
    Front Oncol; 2020; 10():1725. PubMed ID: 32984055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
    Dreger P; Martin S; Kuse R; Sonnen R; Glass B; Kröger N; Parwaresch R; Kneba M; Schmitz N; Haas R
    Hematol J; 2000; 1(2):87-94. PubMed ID: 11920175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
    DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
    Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The clinical characteristics of adult hemophagocytic lymphohistiocytosis treated with haploidentical donor hematopoietic stem cell transplantation].
    Fu L; Wei N; Wang JS; Wu L; Wang YN; Huang DY; Liu JL; Wang Z
    Zhonghua Nei Ke Za Zhi; 2017 Apr; 56(4):273-278. PubMed ID: 28355720
    [No Abstract]   [Full Text] [Related]  

  • 39. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation.
    Colita A; Colita A; Bumbea H; Croitoru A; Orban C; Lipan LE; Craciun OG; Soare D; Ghimici C; Manolache R; Gelatu I; Vladareanu AM; Pasca S; Teodorescu P; Dima D; Lupu A; Coriu D; Tomuleasa C; Tanase A
    Front Oncol; 2019; 9():892. PubMed ID: 31552193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma.
    Yamasaki S; Chihara D; Kim SW; Kawata T; Mizuta S; Ago H; Chou T; Yamane T; Uchiyama H; Oyake T; Miura K; Saito B; Taji H; Nakamae H; Miyamoto T; Fukuda T; Kanda J; Atsuta Y; Suzuki R
    Int J Hematol; 2019 Feb; 109(2):175-186. PubMed ID: 30430419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.